The cost to taxpayers of treating
Washington, D.C.-area military veterans suffering from hepatitis C has
eclipsed $64 million per year, according to a review of U.S. Department
of Veterans Affairs records by the News4 I-Team.
The fast-rising
cost is attributed to a cutting-edge but expensive medication the
agency began dispensing last year to veterans in Virginia, Maryland,
D.C. and West Virginia.
The new
hepatitis C drugs, which are known as Sovaldi and Harvoni, are highly
effective and less likely to cause side effects in patients, doctors and
government officials said. Multiple reports estimate a full treatment
of the medication costs tens of thousands of dollars per patient. Each
individual pill costs an estimated $1,000, according to a report from a U.S. Senate panel.
Agency records
obtained by the I-Team from regional administrators of the U.S.
Department of Veterans Affairs show 701 patients received the treatment
at the Washington DC VA Medical Center in 2015. Those records show more
than 200 patients were administered the medications at the Martinsburg
VA Medical Center and more than 480 patients at Maryland’s VA medical
system last year. In all, the cost of treatment exceeded $64 million,
which is a $50 million increase from the cost of Hepatitis C treatment
in 2014.
All costs are covered by the U.S. Department of Veterans Affairs and federal taxpayers.
Nationwide, the
VA estimates the new treatment will cost $1 billion in 2016. But the
agency said it has secured enough funding to expand the dispensation of
the medicine to an increasing number of vets.
“We’re honored
to be able to expand treatment for veterans who are afflicted with
hepatitis C,” VA Undersecretary for Health Dr. David Shulkin said in a
statement. “To manage limited resources previously, we established
treatment priority for the sickest patients. “
Chris Goldzwig,
a military veteran from Brunswick, Maryland, said his treatment of
Harvoni saved him from suffering severe liver failure.
“It’s a miracle,” Goldzwig said. “If it wasn’t for this medicine, I wouldn’t be here.”
Goldzwig, who
received his treatment over the course of 16 weeks at the Martinsburg VA
Medical Center, said the Harvoni pills were less rigorous and
physically challenging than his previous hepatitis C treatment, an
interferon regimen that Goldzwig called nauseating.
Dr. Evelio
Bravo, a physician at the Martinsburg VA Medical Center, said the pills
have a very high success rate with local patients.
“Years ago,
the (older) treatment was very complicated with side effects,” Bravo
said. “The patient would feel ill during the treatment.”
“VA has long
led the country in screening for and treating hepatitis C,” a statement
from the U.S. Department of Veterans Affairs said. “VA has treated over
76,000 Veterans infected with hepatitis C and approximately 60,000 have
been cured.”
Members of
Congress have criticized the manufacturer of the medicine for not
offering a deeper discount to the U.S. Department of Veterans Affairs.
“America's
veterans deserve the same affordable access to life-saving medications
such as sofosbuvir that Gilead is providing to patients in developing
countries. If that’s not happening, the company’s leaders need to
explain why,” said Rep. Jeff Miller (R-FL), chairman of the U.S. House
Veterans Affairs Committee.
A spokeswoman for Gilead, the manufacturer of Sovaldi and Harvoni, said price discounts are offered for the medication.
“Most payers
receive substantial discounts off this price, with the steepest
discounts going to payers like Medicaid and the VA,” spokeswoman Cara
Miller said. “Both the VA and Medicaid currently receive discounts in
excess of 50 percent on Harvoni. With these rebates and discounts, the
prices today are less than the cost of prior regimens.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.